Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
OcugenOCGN |
-$5.5M |
 |
Gilead SciencesGILD |
-$4.04B |
 |
AmgenAMGN |
-$189M |
 |
Editas MedicineEDIT |
-$7M |
 |
Crispr TherapeuticsCRSP |
-$171M |
Are ArriVent BioPharma Insiders Buying or Selling?
ArriVent BioPharma (AVBP) has had no reported insider transactions in the past 90 days. The most recent was HILLHOUSE INVESTMENT MANAGEMENT, LTD., who sold 555,555 shares at $23.37 on December 10, 2025.
Insider trading patterns can signal confidence or concern from the people who know the company best. AltIndex tracks insider transactions as one of 25+ alternative data signals in the AVBP AI Score. For government officials trading this stock, see AVBP congressional trading.
Recent ArriVent BioPharma Insider Transactions
| Insider | Transaction Date | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| HILLHOUSE INVESTMENT MANAGEMENT, LTD. | Dec 10, 2025 | Sell | 555,555 | $23.37 | $13M |
Frequently Asked Questions: ArriVent BioPharma Insider Trading
ArriVent BioPharma insiders have not reported any transactions in the past 90 days.
The most recent sale was by HILLHOUSE INVESTMENT MANAGEMENT, LTD. who sold 555,555 shares on December 10, 2025. View all transactions in the table on this page.
Insider buying is generally a stronger signal than insider selling, since insiders may sell for personal reasons (diversification, taxes) but typically buy only when they believe the stock is undervalued. AltIndex uses insider transaction patterns alongside 25+ other signals in the AI Score.
HILLHOUSE INVESTMENT MANAGEMENT, LTD. has sold the most AVBP stock in the last 2 years, with a total value of $13M.
The total value of insider transactions for ArriVent BioPharma in the last 2 years is negative, amounting to -$13M. This suggests that insiders have predominantly sold shares, which could reflect various personal or financial considerations rather than a straightforward outlook on the company's future performance.
